Rapt’s RPT193 in atopic dermatitis drops by 13 points
RAPT Therapeutics' RPT193 for atopic dermatitis saw its Phase Transition Success Rate drop to 78% despite positive Phase Ib trial results. The drug showed a 36.3% improvement in EASI score over placebo. RPT193's Likelihood of Approval decreased to 3%. Rapt plans a Phase IIb trial, targeting CCR4 on Th2 cells.
Related Clinical Trials
Reference News
Rapt’s RPT193 in atopic dermatitis drops by 13 points
RAPT Therapeutics' RPT193 for atopic dermatitis saw its Phase Transition Success Rate drop to 78% despite positive Phase Ib trial results. The drug showed a 36.3% improvement in EASI score over placebo. RPT193's Likelihood of Approval decreased to 3%. Rapt plans a Phase IIb trial, targeting CCR4 on Th2 cells.